Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR2M7L)

Drug Name

ATN-658 Drug Info

Synonyms

ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMR2M7L

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Urokinase-type plasminogen activator (PLAU)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pro-urokinase	DMGKT2L	Thrombin deficiency	3B14.Z	Approved	[1]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[2]
PAI-1	DMY2AEF	N. A.	N. A.	Phase 4	[3]
Amediplase	DM4FPM3	Myocardial infarction	BA41-BA43	Phase 3	[4]
Upamostat	DMFZULI	Breast cancer	2C60-2C65	Phase 2	[5]
Saruplase	DM1M0PR	Thrombosis	DB61-GB90	Phase 2	[6]
HTU-PA	DMNHE43	Cerebrovascular ischaemia	8B1Z	Phase 1/2	[7]
PMID18163548C4	DMHPME3	Myocardial ischemia	BA6Z	Clinical trial	[8]
UK-356202	DMSRK2A	Myocardial hypertrophy	BC45	Clinical trial	[9]
PAI-2	DMRSMW8	N. A.	N. A.	Discontinued in Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Urokinase-type plasminogen activator (PLAU)	TTGY7WI	UROK_HUMAN	Activator	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
4	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
5	Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
6	Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
7	Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
8	Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6.
9	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
10	Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41.